Toronto – (business wire)– Biomind Labs Inc. (“biomind lab” or “company) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) develops next-generation medicines to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the efficacy of psychedelic molecules is a leading biotechnology company focused on is pleased to announce the successful development of a new sublingual formulation for use in a Phase II trial of 5-Metoxi-N,N-dimethyltryptamine (see5-MeO-DMT‘)-based BMND08 candidates have potential for the treatment of depression and anxiety in Alzheimer’s disease.
“A new milestone has been reached that strengthens our vertical integration strategy. We have completed production of the first batch of new drug candidates that may enable us to pursue a new line of development to reduce depression and anxiety conditions in patients with Alzheimer’s disease. We are very excited. Over the past few decades, science has proven that life expectancy can be increased, but this perception may not be as good as hoped.? Current lifestyles due to Covid-19, The routine, long-lasting neurological consequences, and consequences of lack of brain training have turned neurodegenerative diseases into common diseases. For those who have relatives with neurodegenerative diseases such as Alzheimer’s disease, there are invisible, slow and irreversible effects that completely destroy quality of life. The sublingual route of administration addresses many drug and patient needs and is useful for the elderly and psychiatric uncooperative patients with dysphagia (dysphagia). Highlights convenient dosing: sublingual administration has several advantages over oral formulations, including rapid absorption, predictable efficacy, reduced interactions with other medications and foods, and ease of administration The sublingual tablets have been delivered to the site and a Phase II trial will be initiated upon arrival.
“Our main objectives in developing this formulation were based on providing a pain-free and scalable formulation that is inexpensive, convenient for repeated and long-term use. It is degraded by monoamine oxidase enzymes present in the gastrointestinal tract, preventing absorption into the circulatory and central nervous system, rendering it neurochemically inactive after oral administration. The addition of a monoamine oxidase inhibitor to protect the -MeO-DMT will be critical, as this factor significantly increases formulation complexity to maximize outcomes.”
About Biomind Lab Co., Ltd.
Biomind Labs is a biotechnology research and development company dedicated to translating knowledge in biomedical science into new pharmaceuticals and innovative nanotechnology delivery systems for a variety of psychiatric and neurological conditions. Biomind Labs has developed a key psychedelic molecule, N,N-dimethyltryptamine (“DMT”), 5-MeO-DMT and mescaline treat a wide range of therapeutic indications. Biomind Labs’ focus is on providing patients with affordable, modern therapies.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of applicable Canadian securities laws. All statements other than statements of historical fact are forward-looking information and are based on expectations, estimates and projections as of the date of this news release. Any statement discussing predictions, expectations, beliefs, plans, predictions, objectives, assumptions, future events, or performance (phrases such as “expect,” “do not expect,” “expect,” “predict,” etc.) is not always used) or “not expected”, “planned”, “budgeted”, “intended”, “forecast”, “estimate”, “believe”, “intend”, or such “could” or “could”, “could”, “could”, or “could” refer to variations of a word or phrase or a particular action, event or outcome “to be” is considered to occur or be achieved) may be forward-looking information rather than statements of historical fact. Forward-looking statements in this document include, among other things, statements regarding our ability to scientifically harness the efficacy of psychedelic molecules to treat patients suffering from neurological and psychiatric disorders; Contains our description of the exam. Candidate BMND08; company statement on its focus on potential solutions to these devastating diseases and potential improvements in neuroplasticity. Our ability to provide patients with access to affordable and modern treatments. and other statements that are not historical facts.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or other Future events may differ materially from any future results, performance or achievements expressed or implied by us. such forward-looking statements. Such factors and risks include, among others: (b) Comply with Extensive Government Regulations. (c) domestic and foreign laws and regulations may adversely affect our business and results of operations; (d) Stock markets experience volatility that is often unrelated to company performance, and these fluctuations may adversely affect the price of our securities, regardless of their peers. (e) A negative change in public perception of tryptamine-based and psychedelic-based therapies. (f) Impact of COVID-19. (g) general business, economic, competitive, political and social uncertainties; Readers should therefore not place undue reliance on the forward-looking information contained in this press release.
We make no claims of medical, therapeutic, or health benefits for the products we suggest. The U.S. Food and Drug Administration, Health Canada, or other similar regulatory agencies have not evaluated claims regarding tryptamine-based treatments, psychedelic-based treatments, or other psychedelic compounds. There is no guarantee that the use of psychedelic tryptamine, tryptamine derivatives, or other psychedelic compounds will diagnose, treat, cure, or prevent any disease or condition. Substantial scientific research and clinical trials are needed. We have not yet completed any commercial clinical trials for the use of the proposed product. References to the quality, consistency, efficacy and safety of a potential product do not imply that we have so validated in commercial clinical trials or that we have completed such trials. If we are unable to obtain the necessary approvals and research for commercialization, our performance and operations could be materially and adversely affected.
The forward-looking information contained in this news release represents our expectations as of the date of this news release and is therefore subject to change after that date. Readers should not place undue weight on forward-looking information or rely on this information as of any other date. We undertake no obligation to update these forward-looking statements if management’s beliefs, estimates, opinions or other factors change.
Neo Exchange Inc. has not endorsed or disapproved of the content of this news release and is not responsible for the adequacy or accuracy of any content contained herein.
